In a patient with normal left ventricular systolic function (ejection fraction 59%) but right ventricular enlargement, reduced right ventricular systolic function (S' 8.7 cm/s, tricuspid annular plane systolic excursion 1.4 cm), severe tricuspid regurgitation, severe pulmonary hypertension (estimated pulmonary arterial systolic pressure 61 mmHg), dilated inferior vena cava with <50% collapse indicating elevated right atrial pressure, and no pericardial effusion, what are the appropriate next steps in management?

Immediate Evaluation and Management of Severe Right Heart Failure

This patient requires urgent right heart catheterization (RHC) to determine the underlying mechanism of severe pulmonary hypertension and guide definitive management, followed by consideration for tricuspid valve surgery if hemodynamics confirm appropriate candidacy. 1, 2

Critical Diagnostic Next Steps

1. Right Heart Catheterization (Mandatory)

RHC is essential before any intervention to:

• Directly measure pulmonary artery pressures and pulmonary vascular resistance (PVR)
• Differentiate pre-capillary from post-capillary pulmonary hypertension
• Measure pulmonary artery wedge pressure (PAWP) to assess left-sided filling pressures
• Calculate transpulmonary gradient (TPG) and diastolic pressure gradient (DPG)
• Exclude reversible causes (shunts, pulmonary vascular disease) 1, 3

The severe TR may cause underestimation of pulmonary systolic pressure on echo, making invasive measurement critical for accurate diagnosis 1. With severe RV dysfunction (TAPSE 1.4 cm, S' 8.7 cm/s—both markedly reduced), determining whether pulmonary hypertension is reversible versus fixed is paramount before considering surgery.

2. Assess for Underlying Etiologies

Look specifically for:

• Left heart disease: The mild-moderate MR and enlarged left atrium suggest possible post-capillary component (Group 2 PH)
• Chronic thromboembolic disease: Consider CT pulmonary angiography if not already done
• Intrinsic pulmonary vascular disease: History of connective tissue disease, drugs, HIV
• Congenital shunts: Though less likely given age, RHC will detect 3

3. Advanced RV Function Assessment

Consider cardiac MRI if available for:

• Precise RV volumes and ejection fraction (gold standard)
• Assessment of myocardial fibrosis
• Better prognostication 1, 4

Medical Management (Immediate)

Diuretic Therapy

Aggressive diuresis is indicated for systemic congestion 1, 2:

• Loop diuretics (furosemide) titrated to clinical decongestion
• Monitor for low-flow syndrome (hypotension, worsening renal function)
• Consider aldosterone antagonists, especially with hepatic congestion 2
• Target: JVP normalization, resolution of peripheral edema/ascites

Treat Underlying Left Heart Disease

• Optimize management of mitral regurgitation
• Aggressive blood pressure control if hypertensive
• Rate/rhythm control for any atrial fibrillation 2

Pulmonary Vasodilator Therapy (Conditional)

May be considered if RHC demonstrates:

• Elevated PVR (>3 Wood units by older criteria, >2 WU by 2024 criteria) 5
• Acute vasoreactivity during testing
• Pre-capillary or combined pre/post-capillary component 2, 6

Do NOT use empirically—requires hemodynamic confirmation and vasoreactivity testing 2.

Surgical Decision-Making Algorithm

Indications for Tricuspid Valve Surgery

Class I (Recommended) 1, 2, 7:

1. If undergoing left-sided valve surgery: Severe TR should be addressed concomitantly (repair preferred over replacement)
2. Isolated severe TR with symptoms: Surgery indicated if:
   • RV dysfunction is NOT severe and irreversible
   • Pulmonary hypertension is NOT irreversible
   • No severe end-organ damage

Critical Contraindications/High-Risk Features

Surgery carries prohibitive risk if 2, 1:

• Severe, irreversible RV systolic dysfunction (your patient has TAPSE 1.4 cm—severely reduced, normal >16 mm)
• Irreversible pulmonary hypertension (PVR >5 WU, fixed on vasodilator challenge)
• Advanced end-organ damage (hepatic dysfunction, renal failure)

Your patient's TAPSE of 1.4 cm and S' of 8.7 cm/s represent severe RV dysfunction 1, 8, 9. This places them at very high surgical risk and potentially beyond the window for meaningful benefit.

Timing Considerations

The sobering reality: Isolated tricuspid valve surgery after development of severe RV dysfunction carries 10-25% operative mortality 2, 1. Earlier intervention before severe RV dysfunction develops is strongly preferred 1, but this patient presents late.

Specific Management Pathway

If RHC Shows:

Post-capillary PH (PAWP >15 mmHg, PVR <2-3 WU):

• Optimize left heart failure management
• Aggressive diuresis
• Consider tricuspid surgery only if MR requires intervention AND RV function improves with medical therapy

Pre-capillary or Combined PH (PVR ≥3 WU):

• Determine if acute vasoreactivity present
• Consider pulmonary vasodilators if responsive
• Tricuspid surgery only if PVR improves and RV shows recovery potential

Fixed, Severe PH with Severe RV Dysfunction:

• Medical management only (diuretics, treat underlying causes)
• Consider advanced heart failure therapies/transplant evaluation if age-appropriate
• Transcatheter tricuspid repair may be considered as palliative option 1

Common Pitfalls to Avoid

1. Operating on severe TR with irreversible RV dysfunction: High mortality, minimal benefit 2, 1
2. Assuming echo-estimated PA pressure is accurate with severe TR: Always confirm with RHC 1
3. Empiric pulmonary vasodilators without hemodynamic confirmation: May worsen post-capillary PH 2
4. Overly aggressive diuresis: Can precipitate low-flow syndrome in RV failure 2
5. Delaying evaluation: This patient needed assessment before severe RV dysfunction developed 1

Prognosis and Counseling

With TAPSE 1.4 cm, this patient has advanced RV dysfunction 8, 9. Even with optimal management, prognosis is guarded. The elevated RA pressure (15 mmHg), dilated IVC, and severe TR with RV enlargement indicate Stage D (symptomatic severe) disease 1. Survival benefit from intervention at this stage is uncertain and depends entirely on reversibility of pulmonary hypertension and potential for RV recovery 1, 10.

The most recent guidelines emphasize that RV function is the principal determinant of outcomes in severe TR 8, and your patient's severely reduced TAPSE and S' values predict poor outcomes regardless of intervention type.